Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07539584Not ApplicableCompleted

Adiponectin in Patients With Metabolic Disorders

Role: collaborator

NCT06839768Not ApplicableRecruiting

Safety and Efficacy of MILEP Versus Standard EEP

Role: lead

NCT05994716Not ApplicableEnrolling By Invitation

Telemonitoring for IBD Goodness Examination in Russia

Role: collaborator

NCT05455151Phase 1Completed

Hysteroscopic Injections of Autologous Endometrial Cells and Platelet-rich Plasma in Patients With Thin Endometrium

Role: collaborator

NCT05284929Unknown

Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population

Role: lead

All 5 trials loaded